


The Hospital Medicines List (HML)

Section H

for Hospital Pharmaceuticals

Update effective 1 July 2015

Cumulative for April, May, June and July 2015



Contents

Summary of decisions effective 1 July 2015	3
Section H changes to Part II	10
Index	36

Summary of decisions

EFFECTIVE 1 JULY 2015

- Acetylcysteine (DBL Acetylcysteine) inj 200 mg per ml, 10 ml ampoule – new listing and addition of HSS
- Acetylcysteine (Martindale Acetylcysteine) inj 200 mg per ml, 10 ml ampoule – to be delisted 1 September 2015
- Acetylcysteine (Acetadote) inj 200 mg per ml, 30 ml ampoule – to be delisted 1 September 2015
- Amoxicillin with clavulanic acid (m-Amoxiclav) inj 500 mg with clavulanic acid 100 mg vial – addition of HSS
- Amoxicillin with clavulanic acid (m-Amoxiclav) inj 1,000 mg with clavulanic acid 200 mg vial – price decrease and addition of HSS
- Amphotericin B (AmBisome) inj (liposomal) 50 mg vial – addition of HSS
- Atenolol (Mylan Atenolol) tab 50 mg and 100 mg – price decrease and addition of HSS
- Azithromycin (Apo-Azithromycin) tab 250 mg and 500 mg – price decrease and addition of HSS
- Baclofen (Lioresal Intrathecal) inj 0.05 mg per ml, 1 ml ampoule – addition of HSS
- Benzathine benzylpenicillin (Bicillin LA) inj 900 mg (1.2 million units) in 2.3 ml syringe – addition of HSS
- Betamethasone dipropionate with calcipotriol (Daivobet) gel 500 mcg with calcipotriol 50 mcg per g, 30 g and oint 500 mcg with calcipotriol 50 mcg per g, 30 g – addition of HSS
- Bupivacaine hydrochloride (Marcain) inj 2.5 mg per ml, 20 ampoule sterile pack, inj 5 mg per ml, 10 ml ampoule sterile pack, and inj 5 mg per ml, 20 ml ampoule sterile pack – price decrease and addition of HSS
- Cabergoline (Dostinex) tab 0.5 mg, 2 and 8 tab pack size – price decrease and addition of HSS
- Candesartan cilexetil (Candestar) tab 4 mg, 8 mg, 16 mg and 32 mg – price decrease and addition of HSS
- Carboplatin (DBL Carboplatin) inj 10 mg per ml, 5 ml, 15 ml and 45 ml vial – new listing and addition of HSS
- Carboplatin (Carboplatin Ebewe) inj 10 mg per ml, 5 ml and 100 ml vial – to be delisted 1 September 2015
- Carboplatin (Carbaccord) inj 10 mg per ml, 15 ml and 45 ml vial – to be delisted 1 September 2015
- Carmustine (BiCNU) inj 100 mg vial – new listing and addition of HSS

Summary of decisions – effective 1 July 2015 (continued)

- Cefalexin (Cefalexin Sandoz) grans for oral liq 25 mg per ml and 50 mg per ml – price decrease and addition of HSS
 - Celiprolol (Celol) tab 200 mg – price increase
 - Chloramphenicol (Chlorafast) eye drops 0.5%, 10 ml – price decrease and addition of HSS
 - Chlorhexidine gluconate (healthE) mouthwash 0.2%, 200 ml – price decrease and addition of HSS
 - Chlorhexidine gluconate (healthE) crm 1%, 50 g – amended chemical name, price decrease and addition of HSS
 - Chlorhexidine gluconate (healthE) lotn 1%, 200 ml – price decrease and addition of HSS
 - Ciclopirox olamine (Apo-Ciclopirox) nail soln 8%, 7 ml – new listing and additions of HSS
 - Ciclosporin (Sandimmun) inj 50 mg per ml, 5 ml ampoule – addition of HSS
 - Clomipramine hydrochloride (Apo-Clomipramine) tab 10 mg and 25 mg – addition of HSS
 - Clonazepam (Paxam) tab 500 mcg and 2 mg – price increase
 - Clonidine hydrochloride (Clonidine BNM) tab 25 mcg – price decrease and addition of HSS
 - Crotamiton (Itch-Soothe) crm 10%, 20 g – price decrease and addition of HSS
 - Daptomycin (Cubicin) inj 350 mg vial and 500 mg vial – new listing and addition of HSS
 - Diphtheria, tetanus and pertussis vaccine (Boostrix) inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – amended restriction
 - Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine (Infanrix-hex) inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial – amended restriction
 - Dopamine hydrochloride (DBL Sterile Dopamine Concentrate) inj 40 mg per ml, 5 ml ampoule – new listing and addition of HSS
 - Dopamine hydrochloride (Martindale) inj 40 mg per ml, 5 ml ampoule – to be delisted 1 September 2015
 - Doxorubicin hydrochloride inj 2 mg per ml, 5 ml vial, 25 mg vial, 50 ml vial and 100 mg vial, and 50 mg vial – DV Limit note removed
-

Summary of decisions – effective 1 July 2015 (continued)

- Efavirenz (Stocrin) tab 50 mg, 200 mg and 600 mg – price decrease and addition of HSS
 - Enalapril maleate (Ethics Enalapril) tab 5 mg, 10 mg and 20 mg – price decrease and addition of HSS
 - Entacapone (Entapone) tab 200 mg – price decrease and addition of HSS
 - Ertapenem (Invanz) inj 1 g vial – price increase
 - Ethinyloestradiol (NZ Medical & Scientific) tab 10 mcg – new listing and addition of HSS
 - Etidronate disodium (Arrow-Etidronate) tab 200 mg – price decrease and addition of HSS
 - Felodipine (Plendil ER) tab long-acting 2.5 mg, 5 mg and 10 mg – price decrease and addition of HSS
 - Fentanyl (Boucher and Muir) inj 50 mcg per ml, 2 ml ampoule and 10 ml ampoule – price decrease and addition of HSS
 - Flucloxacillin (Staphlex) cap 250 mg and 500 mg – price decrease and addition of HSS
 - Flucloxacillin (AFT) grans for oral liq 25 mg per ml and 50 mg per ml – price decrease and addition of HSS
 - Flucloxacillin (Flucloxin) inj 1 g vial – HSS suspended
 - Flucloxacillin (DBL Flucloxacillin) inj 1 g vial – new listing
 - Fludarabine phosphate (Fludara Oral) tab 10 mg – price decrease and addition of HSS
 - Flumazenil (Anexate) inj 0.1 mg per ml, 5 ml ampoule – price decrease and addition of HSS
 - Fluorometholone (FML) eye drops 0.1%, 5 ml – new listing and addition of HSS
 - Fluorometholone (Flucon) eye drops 0.1%, 5 ml – to be delisted 1 September 2015
 - Fluorouracil sodium (Efudix) crm 5%, 20 g – price decrease and addition of HSS
 - Fluticasone propionate (Flixonase Hayfever & Allergy) nasal spray 50 mcg per dose, 120 dose – price decrease and addition of HSS
 - Furosemide [frusemide] (Diurin 40) tab 40 mg – price decrease and addition of HSS
 - Furosemide [frusemide] (Urex Forte) tab 500 mg – addition of HSS
 - Gentamicin sulphate (Pfizer) inj 40 mg per ml, 2 ml ampoule – price decrease and addition of HSS
-

Summary of decisions – effective 1 July 2015 (continued)

- Glipizide (Minidiab) tab 5 mg – price decrease and addition of HSS
- Glycerol (PSM) suppos 3.6 g – addition of HSS
- Haemophilus influenzae type B vaccine (Act-HIB) inj 10 mcg vial with diluent syringe – amended restriction
- Hepatitis B recombinant vaccine (HBvaxPRO) inj 5 mcg in 0.5 ml vial and inj 10 mcg in 1 ml vial – amended restriction
- Human papillomavirus (6, 11, 16 and 18) vaccine [HPV] (Gardasil) inj 120 mcg in 0.5 ml syringe – amended restriction
- Hydrocortisone (Douglas) tab 5 mg and 20 mg – addition of HSS
- Hydrocortisone with miconazole (Micreme H) crm 1% with miconazole nitrate 2%, 15 g – price decrease and addition of HSS
- Hydroxocobalamin (Neo-B12) inj 1 mg per ml, 1 ml ampoule – amended chemical name, new listing and addition of HSS
- Hydroxocobalamin (ABM Hydroxocobalamin) inj 1 mg per ml, 1 ml ampoule – to be delisted 1 September 2015
- Hydroxychloroquine (Plaquenil) tab 200 mg – price decrease and addition of HSS
- Hyoscine butylbromide (Gastrosoothe) tab 10 mg – price increase
- Iloprost (Arrow-Iloprost) inj 50 mcg in 0.5 ml ampoule – HSS delayed
- Influenza vaccine (Fluarix and Influvac) inj 45 mcg in 0.5 ml syringe – amended restriction
- Irinotecan hydrochloride (Irinotecan Actavis 40) inj 20 mg per ml, 2 ml vial – price increase and addition of HSS
- Irinotecan hydrochloride (Irinotecan Actavis 100) inj 20 mg per ml, 5 ml vial – price decrease and addition of HSS
- Isoniazid (PSM) tab 100 mg – addition of HSS
- Isoniazid with rifampicin (Rifinah) tab 100 mg with rifampicin 150 mg and 150 mg with rifampicin 300 mg – new listing and addition of HSS
- Latanoprost (Hysite) eye drops 0.005%, 2.5 ml – price decrease and addition of HSS
- Lidocaine [lignocaine] hydrochloride (Orion) gel 2%, 20 ml – addition of HSS
- Linezolid (Zyvox) tab 600 mg, oral liq 20 mg per ml, and inj 2 mg per ml, 300 ml bag – new listing and addition of HSS
- Lithium carbonate (Lithicarb FC) tab 250 mg and 400 mg – addition of HSS

Summary of decisions – effective 1 July 2015 (continued)

- Meningococcal (A, C, Y and W-135) conjugate vaccine (Menactra) inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – amended restriction
 - Measles, mumps and rubella vaccine (M-M-R II) Inj 1000 TCID₅₀ measles, 12500 TCID₅₀ mumps and 1000 TCID₅₀ rubella vial with diluent – amended restriction
 - Meningococcal C conjugate vaccine (Neisvac-C) inj 10 mcg in 0.5 ml syringe – amended restriction
 - Mesalazine (Pentasa) enema 1 g per 100 ml – price decrease and addition of HSS
 - Methadone hydrochloride (Methatabs) tab 5 mg – addition of HSS
 - Methadone hydrochloride (Biodone Forte) oral liq 5 mg per ml – price decrease and addition of HSS
 - Methadone hydrochloride oral liq 2 mg per ml (Biodone) and 10 mg per ml (Biodone Extra Forte) – addition of HSS
 - Methotrexate (Trexate) tab 2.5 mg and 10 mg – price decrease and addition of HSS
 - Miconazole (Decozol) oral gel 20 mg per g, 40 g – price decrease and addition of HSS
 - Mitozantrone (Mitozantrone Ebewe) inj 2 mg per ml, 10 ml vial – price decrease and addition of HSS
 - Mitozantrone inj 2 mg per ml, 5 ml vial (Mitozantrone Ebewe) and inj 2 mg per ml, 12.5 ml vial (Onkotrone) – to be delisted 1 September 2015
 - Mometasone furoate (Elocon) lotn 0.1%, 30 ml – new listing and addition of HSS
 - Naproxen tab 250 mg (Noflam 250) and 500 mg (Noflam 500) – price decrease and addition of HSS
 - Nicotine (Habitrol) gum (classic, fruit and mint) 2 mg and 4 mg, patch 7 mg, 14 mg and 21 mg, and lozenge 1 mg and 2 mg – price decrease
 - Oxytocin with ergometrine maleate (Syntometrine) inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – addition of HSS
 - Paraffin (healthE) white soft, 10 g – price decrease and addition of HSS
 - Pizotifen (Sandomigran) tab 500 mcg – addition of HSS
 - Pneumococcal (PCV13) conjugate vaccine (Prevenar 13) inj 30.8 mcg in 0.8 ml syringe – amended restriction
 - Potassium chloride (Span-K) tab long-acting 600 mg (8 mmol) – addition of HSS
-

Summary of decisions – effective 1 July 2015 (continued)

- Pregnancy test – HCG urine (EasyCheck) cassette – new listing and addition of HSS
- Pregnancy test – HCG urine (Innovacon hCG One Step Pregnancy Test) cassette – to be delisted 1 September 2015
- Promethazine hydrochloride (Allersoothe) tab 10 mg and 25 mg, and oral liq 1 mg per ml – price decrease and addition of HSS
- Propranolol (Cardinol LA) cap long-acting 160 mg – price increase
- Quinapril (Arrow-Quinapril 5) tab 5 mg – price increase and addition of HSS
- Quinapril tab 10 mg (Arrow – Quinapril 10) and tab 20 mg (Arrow-Quinapril 20) – price decrease and addition of HSS
- Salbutamol (Asthalin) nebuliser soln 1 mg per ml, 2.5 ml ampoule and 2 mg per ml, 2.5 ml ampoule – price decrease and addition of HSS
- Salbutamol with ipratropium bromide (Duoliln) nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – price decrease and addition of HSS
- Sildenafil (Vedafil) tab 25 mg, 50 mg and 100 mg – new listing and addition of HSS
- Sildenafil (Silagra) tab 25 mg, 50 mg and 100 mg – to be delisted 1 September 2015
- Sodium chloride (BD PosiFlush) inj 0.9%, 3 ml, 5 ml and 10 ml syringe, non-sterile pack – amended presentation description
- Sodium hyaluronate [hyaluronic acid] inj 20 mg per ml, 1 ml syringe – amended chemical name
- Sodium hyaluronate [hyaluronic acid] inj 14 mg per ml, 0.85 ml syringe and 0.55 ml syringe (Healon GV), inj 23 mg per ml, 0.6 ml syringe, and inj 10 mg per ml, 0.85 ml syringe (Provisc) – amended chemical name
- Sodium hyaluronate [hyaluronic acid] with chondroitin sulphate inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe (Duovisc), inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe (Duovisc), and 30 mg with chondroitin sulphate 40 mg per m, 0.75 ml syringe – amend chemical name and presentation description
- Sodium hyaluronate [hyaluronic acid] eye drops 1 mg per ml, 10 ml – amended chemical name
- Sodium polystyrene sulphonate (Resonium A) powder, 454 g – new listing and addition of HSS

Summary of decisions – effective 1 July 2015 (continued)

- Sodium valproate (Epilim IV) inj 100 mg per ml, 4 ml vial – new listing and addition of HSS
- Testosterone undecanoate (Andriol Testocaps) cap 40 mg – price decrease and addition of HSS
- Tranexamic acid (Cyklokapron) inj 100 mg per ml, 5 ml ampoule – price decrease and addition of HSS
- Trimethoprim (TMP) tab 300 mg – price increase
- Tropisetron (Tropisetron-AFT) inj 1 mg per ml, 2 ml ampoule and 5 ml ampoule – addition of HSS
- Venlafaxine (Efexor XR) cap modified release 37.5 mg, 75 mg and 150 mg – price decrease
- Vinorelbine (Navelbine) inj 10 mg per ml, 1 ml vial and 5 ml vial – price decrease and addition of HSS

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 July 2015

ALIMENTARY TRACT AND METABOLISM

15	MESALAZINE (↓ price and addition of HSS) Enema 1 g per 100 ml – 1% DV Sep-15 to 2018	41.30	7	Pentasa
16	HYOSCINE BUTYLBROMIDE (↑ price) Tab 10 mg	2.18	20	Gastrosoothe
19	GLIPIZIDE (↓ price and addition of HSS) Tab 5 mg – 1% DV Sep-15 to 2018	2.85	100	Minidiab
21	GLYCEROL (addition of HSS) Suppos 3.6 g – 1% DV Sep-15 to 2018	6.50	20	PSM
24	CHLORHEXIDINE GLUCONATE (↓ price and addition of HSS) Mouthwash 0.2% – 1% DV Sep-15 to 2018	2.57	200 ml	healthE
24	MICONAZOLE (↓ price and addition of HSS) Oral gel 20 mg per g – 1% DV Sep-15 to 2018	4.79	40 g	Decozol
24	SODIUM HYALURONATE [HYALURONIC ACID] (amended chemical name) → Inj 20 mg per ml, 1 ml syringe			
25	HYDROXOCOBALAMIN ACETATE (amended chemical name, new listing and addition of HSS) Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-15 to 2018	2.31	3	Neo-B12
	Note – ABM Hydroxocobalamin inj 1 mg per ml, 1 ml ampoule to be delisted from 1 September 2015.			

BLOOD AND BLOOD FORMING ORGANS

30	TRANEXAMIC ACID (↓ price and addition of HSS) Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	55.00	10	Cyklokapron
36	SODIUM CHLORIDE (amended presentation description) → Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018	10.65	30	BD PosiFlush
	Restricted For use in flushing of in-situ vascular access devices only.			
	→ Inj 0.9%, 5 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018	10.80	30	BD PosiFlush
	Restricted For use in flushing of in-situ vascular access devices only.			
	→ Inj 0.9%, 10 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018	11.25	30	BD PosiFlush
	Restricted For use in flushing of in-situ vascular access devices only.			
37	POTASSIUM CHLORIDE (addition of HSS) Tab long-acting 600 mg (8 mmol) – 1% DV Sep-15 to 2018	7.42	200	Span-K

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

37	SODIUM POLYSTYRENE SULPHONATE (new listing) Powder – 1% DV Sep-15 to 2018	84.65	454 g	Resonium A
----	------------------------------------------------------------------------------------	-------	-------	-------------------

CARDIOVASCULAR SYSTEM

38	ENALAPRIL MALEATE (↓ price and addition of HSS) Tab 5 mg – 1% DV Sep-15 to 2018	0.96	100	Ethics Enalapril
	Tab 10 mg – 1% DV Sep-15 to 2018	1.24	100	Ethics Enalapril
	Tab 20 mg – 1% DV Sep-15 to 2018	1.78	100	Ethics Enalapril
38	QUINAPRIL (addition of HSS) Tab 5 mg – 1% DV Sep-15 to 2018 (↑ price)	4.31	90	Arrow-Quinapril 5
	Tab 10 mg – 1% DV Sep-15 to 2018 (↓ price).....	3.15	90	Arrow-Quinapril 10
	Tab 20 mg – 1% DV Sep-15 to 2018 (↓ price).....	5.97	90	Arrow-Quinapril 20
39	CANDESARTAN CILEXETIL (↓ price and addition of HSS) → Tab 4 mg – 1% DV Sep-15 to 2018	2.50	90	Candestar
	→ Tab 8 mg – 1% DV Sep-15 to 2018	3.68	90	Candestar
	→ Tab 16 mg – 1% DV Sep-15 to 2018	6.12	90	Candestar
	→ Tab 32 mg – 1% DV Sep-15 to 2018	10.66	90	Candestar
40	ATENOLOL (↓ price and addition of HSS) Tab 50 mg – 1% DV Sep-15 to 2018	4.61	500	Mylan Atenolol
	Tab 100 mg – 1% DV Sep-15 to 2018	7.67	500	Mylan Atenolol
41	CELIPROLOL (↑ price) Tab 200 mg	21.40	180	Celol
41	PROPRANOLOL (↑ price) Cap long-acting 160 mg	18.17	100	Cardinol LA
42	FELODIPINE (↓ price and addition of HSS) Tab long-acting 2.5 mg – 1% DV Sep-15 to 2018	1.45	30	Plendil ER
	Tab long-acting 5 mg – 1% DV Sep-15 to 2018	1.55	30	Plendil ER
	Tab long-acting 10 mg – 1% DV Sep-15 to 2018	2.30	30	Plendil ER
43	CLONIDINE HYDROCHLORIDE (↓ price and addition of HSS) Tab 25 mcg – 1% DV Sep-15 to 2018.....	10.53	112	Clonidine BNM
43	FUROSEMIDE (FRUSEMIDE) (↓ price and addition of HSS) Tab 40 mg – 1% DV Sep-15 to 2018	8.00	1,000	Diurin 40
43	FUROSEMIDE (FRUSEMIDE) (addition of HSS) Tab 500 mg – 1% DV Sep-15 to 2018	25.00	50	Urex Forte
46	DOPAMINE HYDROCHLORIDE (new listing) Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	16.89	5	DBL Sterile Dopamine Concentrate

Note – Martindale inj 40 mg per ml, 5 ml ampoule to be delisted from 1 September 2015.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

48	SILDENAFIL (new listing)			
	→ Tab 25 mg – 1% DV Sep-15 to 2018	0.75	4	Vedafil
	→ Tab 50 mg – 1% DV Sep-15 to 2018	0.75	4	Vedafil
	→ Tab 100 mg – 1% DV Sep-15 to 2018	2.75	4	Vedafil
	Note – Silagra tab 25 mg, 50 mg and 100 mg to be delisted from 1 September 2015.			
48	ILOPROST (HSS delayed)			
	Inj 50 mcg in 0.5 ml ampoule			
	– 1% DV Jul-15 Sep-15 to 2016	89.50	1	Arrow-Iloprost

DERMATOLOGICALS

49	CICLOPIROX OLAMINE (new listing)			
	Nail soln 8% – 1% DV Sep-15 to 2018	6.50	7 ml	Apo-Ciclopirox
50	CROTAMITON (↓ price and addition of HSS)			
	Crnm 10% – 1% DV Sep-15 to 2018	3.37	20 g	Itch-Soothe
51	PARAFFIN (↓ price and addition of HSS)			
	White soft – 1% DV Sep-15 to 2018	0.85	10 g	healthE
	Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.			
52	MOMETASONE FUROATE (new listing)			
	Lotn 0.1% – 1% DV Sep-15 to 2018	7.35	30 ml	Elocon
53	BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL (addition of HSS)			
	Gel 500 mcg with calcipotriol 50 mcg per g			
	– 1% DV Sep-15 to 2018	26.12	30 g	Daivobet
	Oint 500 mcg with calcipotriol 50 mcg per g			
	– 1% DV Sep-15 to 2018	26.12	30 g	Daivobet
53	HYDROCORTISONE WITH MICONAZOLE (↓ price and addition of HSS)			
	Crnm 1% with miconazole nitrate 2%			
	– 1% DV Sep-15 to 2018	2.00	15 g	Micreme H
54	FLUOROURACIL SODIUM (↓ price and addition of HSS)			
	Crnm 5% – 1% DV Sep-15 to 2018	8.95	20 g	Efudix

GENITO-URINARY SYSTEM

55	CHLORHEXIDINE GLUCONATE (amended chemical description, ↓ price and addition of HSS)			
	Crnm 1% – 1% DV Sep-15 to 2018	1.21	50 g	healthE
55	CHLORHEXIDINE GLUCONATE (↓ price and addition of HSS)			
	Lotn 1%, 200 ml – 1% DV Sep-15 to 2018	2.98	1	healthE
57	OXYTOCIN WITH ERGOMETRINE MALEATE (addition of HSS)			
	Inj 5 iu with ergometrine maleate 500 mcg per ml,			
	1 ml ampoule – 1% DV Sep-15 to 2018	11.13	5	Syntometrine

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

HORMONE PREPARATIONS

59	TESTOSTERONE UNDECANOATE (↓ price and addition of HSS) Cap 40 mg – 1% DV Sep-15 to 2018	16.80	60	Andriol Testocaps
60	HYDROCORTISONE (addition of HSS) Tab 5 mg – 1% DV Sep-15 to 2018	8.10	100	Douglas
	Tab 20 mg – 1% DV Sep-15 to 2018	20.32	100	Douglas
61	CABERGOLINE (↓ price and addition of HSS) → Tab 0.5 mg – 1% DV Sep-15 to 2018	4.75	2	Dostinex
		19.00	8	Dostinex
62	ETHINYLLOESTRADIOL (new listing) Tab 10 mcg – 1% DV Sep-15 to 2018	17.60	100	NZ Medical & Scientific

INFECTIONS

69	ERTAPENEM (↑ price) → Inj 1 g vial	73.50	1	Invanz
69	GENTAMICIN SULPHATE (↓ price and addition of HSS) Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	6.00	10	Pfizer
70	CEFALEXIN (↓ price and addition of HSS) Grans for oral liq 25 mg per ml – 1% DV Sep-15 to 2018	8.00	100 ml	Cefalexin Sandoz
	Grans for oral liq 50 mg per ml – 1% DV Sep-15 to 2018	11.00	100 ml	Cefalexin Sandoz
71	AZITHROMYCIN (↓ price and addition of HSS) → Tab 250 mg – 1% DV Sep-15 to 2018	9.00	30	Apo-Azithromycin
	→ Tab 500 mg – 1% DV Sep-15 to 2018	1.05	2	Apo-Azithromycin
72	AMOXICILLIN WITH CLAVULANIC ACID (addition of HSS) Inj 500 mg with clavulanic acid 100 mg vial – 1% DV Sep-15 to 2018	10.14	10	m-Amoxiclav
	Inj 1,000 mg with clavulanic acid 200 mg vial – 1% DV Sep-15 to 2018 (↓ price)	12.80	10	m-Amoxiclav
72	BENZATHINE BENZYL PENICILLIN (addition of HSS) Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Sep-15 to 2018	315.00	10	Bicillin LA
72	FLUCLOXACILLIN (↓ price and addition of HSS) Cap 250 mg – 1% DV Sep-15 to 2018	18.70	250	Staphlex
	Cap 500 mg – 1% DV Sep-15 to 2018	62.90	500	Staphlex
	Grans for oral liq 25 mg per ml – 1% DV Sep-15 to 2018	2.29	100 ml	AFT
	Grans for oral liq 50 mg per ml – 1% DV Sep-15 to 2018	3.08	100 ml	AFT

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

72	FLUCLOXACILLIN (removal of HSS) Inj 1 g vial – 1% DV Sep-14 to 2017 2017 30 Jun 2015	11.60	10	Flucloxin
72	FLUCLOXACILLIN (new listing) Inj 1 g vial	5.80	5	DBL Flucloxacillin
74	DAPTOMYCIN (new listing) → Inj 350 mg vial – 1% DV Sep-15 to 2018	175.16	1	Cubicin
	→ Inj 500 mg vial – 1% DV Sep-15 to 2018	243.52	1	Cubicin
75	AMPHOTERICIN B (addition of HSS) → Inj (liposomal) 50 mg vial – 1% DV Sep-15 to 2018	3,450.00	10	AmBisome
75	LINEZOLID (new listing) → Tab 600 mg – 1% DV Sep-15 to 2018	800.00	10	Zyvox
	→ Oral liq 20 mg per ml – 1% DV Sep-15 to 2018	775.00	150 ml	Zyvox
	→ Inj 2 mg per ml, 300 ml bag – 1% DV Sep-15 to 2018	1,650.00	10	Zyvox
75	TRIMETHOPRIM (↑ price) Tab 300 mg	10.67	50	TMP
78	ISONIAZID (addition of HSS) → Tab 100 mg – 1% DV Sep-15 to 2018	20.00	100	PSM
78	ISONIAZID WITH RIFAMPICIN (new listing) → Tab 100 mg with rifampicin 150 mg – 1% DV Sep-15 to 2018	85.54	100	Rifinah
	→ Tab 150 mg with rifampicin 300 mg – 1% DV Sep-15 to 2018	170.60	100	Rifinah
82	EFAVIRENZ (↓ price and addition of HSS) → Tab 50 mg – 1% DV Sep-15 to 2018	63.38	30	Stocrin
	→ Tab 200 mg – 1% DV Sep-15 to 2018	190.15	90	Stocrin
	→ Tab 600 mg – 1% DV Sep-15 to 2018	63.38	30	Stocrin

MUSCULOSKELETAL SYSTEM

92	HYDROXYCHLOROQUINE (↓ price and addition of HSS) Tab 200 mg – 1% DV Sep-15 to 2018	10.50	100	Plaquenil
94	ETIDRONATE DISODIUM (↓ price and addition of HSS) Tab 200 mg – 1% DV Sep-15 to 2018	13.50	100	Arrow-Etidronate
98	BACLOFEN (addition of HSS) Inj 0.05 mg per ml, 1 ml ampoule – 1% DV Sep-15 to 2018	11.55	1	Lioresal Intrathecal
101	NAPROXEN (↓ price and addition of HSS) Tab 250 mg – 1% DV Sep-15 to 2018	18.06	500	Noflam 250
	Tab 500 mg – 1% DV Sep-15 to 2018	18.91	250	Noflam 500

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 July 2015 (continued)				
NERVOUS SYSTEM				
103	ENTACAPONE (↓ price and addition of HSS) Tab 200 mg – 1% DV Sep-15 to 2018	28.00	100	Entapone
104	BUPIVACAINE HYDROCHLORIDE (↓ price and addition of HSS) Inj 2.5 mg per ml, 20 ml ampoule sterile pack – 1% DV Sep-15 to 2018	29.20	5	Marcain
	Inj 5 mg per ml, 10 ml ampoule sterile pack – 1% DV Sep-15 to 2018	20.25	5	Marcain
	Inj 5 mg per ml, 20 ml ampoule sterile pack – 1% DV Sep-15 to 2018	20.70	5	Marcain
105	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (addition of HSS) Gel 2% – 1% DV Sep-15 to 2018	3.40	20 ml	Orion
108	FENTANYL (↓ price and addition of HSS) Inj 50 mcg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	3.95	10	Boucher and Muir
	Inj 50 mcg per ml, 10 ml ampoule – 1% DV Sep-15 to 2018 ...	10.45	10	Boucher and Muir
108	METHADONE HYDROCHLORIDE (addition of HSS) Tab 5 mg – 1% DV Sep-15 to 2018	1.85	10	Methatabs
108	METHADONE HYDROCHLORIDE (addition of HSS) Oral liq 2 mg per ml – 1% DV Sep-15 to 2018	5.55	200 ml	Biodone
	Oral liq 5 mg per ml – 1% DV Sep-15 to 2018 (↓ price)	5.00	200 ml	Biodone Forte
	Oral liq 10 mg per ml – 1% DV Sep-15 to 2018	6.55	200 ml	Biodone Extra Forte
111	CLOMIPRAMINE HYDROCHLORIDE (addition of HSS) Tab 10 mg – 1% DV Sep-15 to 2018	12.60	100	Apo-Clomipramine
	Tab 25 mg – 1% DV Sep-15 to 2018	8.68	100	Apo-Clomipramine
112	VENLAFAXINE (↓ price) → Cap modified release 37.5 mg	5.69	28	Efexor XR
	→ Cap modified release 75 mg	11.40	28	Efexor XR
	→ Cap modified release 150 mg	13.98	28	Efexor XR
115	SODIUM VALPROATE (new listing) Inj 100 mg per ml, 4 ml vial – 1% DV Sep-15 to 2018	16.60	1	Epilim IV
117	PIZOTIFEN (addition of HSS) Tab 500 mcg – 1% DV Sep-15 to 2018	23.21	100	Sandomigran
118	TROPISETRON (addition of HSS) Inj 1 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	8.95	1	Tropisetron-AFT
	Inj 1 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	13.95	1	Tropisetron-AFT
119	LITHIUM CARBONATE (addition of HSS) Tab 250 mg – 1% DV Sep-15 to 2018	34.30	500	Lithicarb FC
	Tab 400 mg – 1% DV Sep-15 to 2018	12.83	100	Lithicarb FC

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 July 2015 (continued)				
122	CLONAZEPAM (↑ price)			
	Tab 500 mcg	7.53	100	Paxam
	Tab 2 mg	14.37	100	Paxam
127	NICOTINE (↓ price)			
	Gum 2 mg – 1% DV Apr-14 to 2017	22.26	384	Habitrol (Classic) Habitrol (Fruit) Habitrol (Mint)
	Gum 4 mg – 1% DV Apr-14 to 2017	25.67	384	Habitrol (Classic) Habitrol (Fruit) Habitrol (Mint)
	Patch 7 mg per 24 hours – 1% DV Apr-14 to 2017	10.57	28	Habitrol
	Patch 14 mg per 24 hours – 1% DV Apr-14 to 2017	11.31	28	Habitrol
	Patch 21 mg per 24 hours – 1% DV Apr-14 to 2017	11.95	28	Habitrol
	Lozenge 1 mg – 1% DV Apr-14 to 2017	12.91	216	Habitrol
	Lozenge 2 mg – 1% DV Apr-14 to 2017	14.14	216	Habitrol

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

128	CARMUSTINE (new listing)			
	Inj 100 mg vial – 1% DV Sep-15 to 2018	532.00	1	BICNU
128	DOXORUBICIN HYDROCHLORIDE (DV Limit note removed)			
	Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.			
	Inj 2 mg per ml, 5 ml vial			
	Inj 2 mg per ml, 25 ml vial	17.00	1	Arrow-Doxorubicin
	Inj 50 mg vial			
	Inj 2 mg per ml, 50 ml vial			
	Inj 2 mg per ml, 100 ml vial	65.00	1	Arrow-Doxorubicin
129	MITOZANTRONE (↓ price and addition of HSS)			
	Inj 2 mg per ml, 10 ml vial – 1% DV Sep-15 to 2018	97.50	1	Mitozantrone Ebewe
	Note – Mitozantrone Ebewe inj 2 mg per ml, 5 ml vial and Onkotrone inj 2 mg per ml, 12.5 ml vial to be delisted 1 September 2015.			
130	FLUDARABINE PHOSPHATE (↓ price and addition of HSS)			
	Tab 10 mg – 1% DV Sep-15 to 2018	412.00	20	Fludara Oral
130	METHOTREXATE (↓ price and addition of HSS)			
	Tab 2.5 mg – 1% DV Sep-15 to 2018	3.18	30	Trexate
	Tab 10 mg – 1% DV Sep-15 to 2018	21.00	50	Trexate
131	IRINOTECAN HYDROCHLORIDE (addition of HSS)			
	Inj 20 mg per ml, 2 ml vial			
	– 1% DV Sep-15 to 2018 (↑ price)	11.50	1	Irinotecan Actavis 40
	Inj 20 mg per ml, 5 ml vial			
	– 1% DV Sep-15 to 2018 (↓ price)	17.80	1	Irinotecan Actavis 100

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

133	CARBOPLATIN (new listing)			
	Inj 10 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018	15.07	1	DBL Carboplatin
	Inj 10 mg per ml, 15 ml vial – 1% DV Sep-15 to 2018	14.05	1	DBL Carboplatin
	Inj 10 mg per ml, 45 ml vial – 1% DV Sep-15 to 2018	32.59	1	DBL Carboplatin
	Note – Carboplatin Ebewe inj 10 mg per ml, 5 ml vial and 100 ml vial and Carbaccord inj 10 mg per ml, 15 ml vial and 45 ml vial to be delisted 1 September 2015.			
138	VINORELBINE (↓ price and addition of HSS)			
	Inj 10 mg per ml, 1 ml vial – 1% DV Sep-15 to 2018	8.00	1	Navelbine
	Inj 10 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018	40.00	1	Navelbine
140	CICLOSPORIN (addition of HSS)			
	Inj 50 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	276.30	10	Sandimmun

RESPIRATORY SYSTEM AND ALLERGIES

170	FLUTICASONE PROPIONATE (↓ price and addition of HSS)			
	Nasal spray 50 mcg per dose – 1% DV Sep-15 to 2018	2.18	120 dose	Flixonase Hayfever & Allergy
171	PROMETHAZINE HYDROCHLORIDE (↓ price and addition of HSS)			
	Tab 10 mg – 1% DV Sep-15 to 2018	1.78	50	Allersoothe
	Tab 25 mg – 11% DV Sep-15 to 2018	1.99	50	Allersoothe
	Oral liq 1 mg per ml – 1% DV Sep-15 to 2018	2.59	100 ml	Allersoothe
171	SALBUTAMOL WITH IPRATROPIUM BROMIDE (↓ price and addition of HSS)			
	Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Sep-15 to 2018	3.59	20	Duolin
172	SALBUTAMOL (↓ price and addition of HSS)			
	Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Sep-15 to 2018	3.19	20	Asthalin
	Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Sep-15 to 2018	3.29	20	Asthalin

SENSORY ORGANS

176	CHLORAMPHENICOL (↓ price and addition of HSS)			
	Eye drops 0.5% – 1% DV Sep-15 to 2018	0.98	10 ml	Chlorafast
177	FLUOROMETHOLONE (new listing)			
	Eye drops 0.1% – 1% DV Sep-15 to 2018	3.09	5 ml	FML
	Note – Flucon eye drops 0.1% to be delisted from 1 September 2015.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

179	SODIUM HYALURONATE [HYALURONIC ACID] (amended chemical name)			
	Inj 14 mg per ml, 0.85 ml syringe	50.00	1	Healon GV
	Inj 14 mg per ml, 0.55 ml syringe	50.00	1	Healon GV
	Inj 23 mg per ml, 0.6 ml syringe			
	Inj 10 mg per ml, 0.85 ml syringe	30.00	1	Provisc
179	SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE (amended chemical name and presentation description)			
	Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe	64.00	1	Duovisc
	Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe	74.00	1	Duovisc
	Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe			
180	LATANOPROST (↓ price and addition of HSS)			
	Eye drops 0.005% – 1% DV Sep-15 to 2018	1.50	2.5 ml	Hysite
181	SODIUM HYALURONATE [HYALURONIC ACID] (amended chemical name)			
	Eye drops 1 mg per ml	22.00	10 ml	Hylo-Fresh

VARIOUS

182	ACETYLCYSTEINE (new listing)			
	Inj 200 mg per ml, 10 ml ampoule – 1% DV Sep-15 to 2018 ...	78.34	10	DBL Acetylcysteine
	Note – Martindale Acetylcysteine inj 200 mg per ml, 10 ml ampoule to be delisted from 1 September 2015.			
182	ACETYLCYSTEINE (delisting)			
	Inj 200 mg per ml, 30 ml vial	219.00	4	Acetadote
	Note – Acetadote inj 200 mg per ml, 30 ml vial to be delisted from 1 September 2015.			
182	FLUMAZENIL (↓ price and addition of HSS)			
	Inj 0.1 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	85.05	5	Anexate

VACCINES

207	DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE			
	➔ Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial			
	– 1% DV Jul-14 to 2017	0.00	10	Infanrix-hexa
	Restricted			
	Funded for patients meeting any of the following criteria:			
	1 Up to four doses for children up to and under the age of 10 for primary immunisation; or			
	2 Up to four doses (as appropriate) for children are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; renal dialysis and other severely immunosuppressive regimens; or			

continued...

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

continued...

- 2 An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or**

- 3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.**

Note: A course of up-to four vaccines is funded for catch up programmes for children (**up to and under** the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

208 DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE

- Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe

– 1% DV Jul-14 to 2017	0.00	1	Boostrix
		10	Boostrix

Restricted

Funded for any of the following:

- 1 A single vaccine for pregnant woman between gestational weeks 28 and 38 during epidemics; **or-**
- 2 A course of up to four vaccines is funded for children from age 7 **up to the age of 18 to 17** years inclusive to complete full primary immunisation; **or-**
- ~~3 A course of up to four vaccines is funded for children from age 7 to 17 years inclusive for reimmunisation following immunosuppression-~~
- 3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.**

Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

208 HAEMOPHILUS INFLUENZAE TYPE B VACCINE

- Inj 10 mcg vial with diluent syringe – **1% DV Jul-14 to 2017** 0.00 1 **Act-HIB**

Restricted

One dose for patients meeting any of the following:

- 1) For primary vaccination in children; or
- ~~2) For revaccination of children following immunosuppression; or~~
- ~~3) For children aged 0-18 years with functional asplenia; or~~
- ~~4) For patients pre- and post-splenectomy; or~~
- 2) An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or**
- 3 5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.**

208 MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE

- Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – **1% DV Jul-14 to 2017** 0.00 1 **Menactra**

Restricted

Any of the following:

- 1) Up to three doses **and a booster every five years** for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, **HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or**

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

continued...

2) One dose every five years for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

2 3) One dose for close contacts of meningococcal cases; or

3 4) A maximum of two doses for bone marrow transplant patients; or

4 5) A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require **two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly** a second dose three years after the first and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

208 MENINGOCOCCAL C CONJUGATE VACCINE

→ Inj 10 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	1	Neisvac-C
		10	Neisvac-C

Restricted

Any of the following:

1) Up to three doses **and a booster every five years** for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, **HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant**; or

2) One dose every five years for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

2 3) One dose for close contacts of meningococcal cases; or

3 4) A maximum of two doses for bone marrow transplant patients; or

4 5) A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require **two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly** a second dose three years after the first and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

209 PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE

→ Inj 30.8 mcg in 0.5 ml syringe – 1% DV Oct-14 to 2017	0.00	1	Prevenar 13
		10	Prevenar 13

Restricted

Any of the following:

1) A primary course of four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or

2) Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV10; or

3) One dose is funded for high risk children (**over the age of 17 months and up to the age of 18**) who have previously received four doses of PCV10; or

4) Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients with HIV, for patients post **haematopoietic stem cell transplantation HSCT**, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, **complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency** and other severely immunosuppressive regimens up to the age of 18; or

5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

210	HEPATITIS B RECOMBINANT VACCINE → Inj 5 mcg in 0.5 ml vial – 1% DV Jul-14 to 2017 0.00	1	HBvaxPRO
	Restricted Funded for patients meeting any of the following criteria: 1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or 2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or 3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or 4) for HIV positive patients; or 5) for hepatitis C positive patients; or 6) for patients following non-consensual sexual intercourse; or 7) for patients following immunosuppression; or 8) for transplant patients; or 9) following needle stick injury.		
	→ Inj 10 mcg in 1 ml vial – 1% DV Jul-14 to 2017 0.00	1	HBvaxPRO
	Restricted Funded for patients meeting any of the following criteria: 1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or 2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or 3) for children up to under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or 4) for HIV positive patients; or 5) for hepatitis C positive patients; or 6) for patients following non-consensual sexual intercourse; or 7) for patients following immunosuppression; or 8) for transplant patients; or 9) following needle stick injury.		
210	HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] → Inj 120 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017 0.00	10	Gardasil
	Restricted Maximum of three doses for patient meeting any of the following criteria: 1 Females aged under 20 years old; or 2 Patients aged under 26 years old with confirmed HIV infection; or 3 For use in transplant (including stem cell) patients; or 4 An additional dose for patients under 26 years of age post chemotherapy.		
210	INFLUENZA VACCINE (amended restriction) → Inj 45 mcg in 0.5 ml syringe 90.00	10	Fluarix Influvac
	Restricted Any of the following: 1 All people 65 years of age and over; or 2 People under 65 years of age who: 2.1 Have any of the following cardiovascular diseases: 2.1.1 Ischaemic heart disease; or 2.1.2 Congestive heart disease failure ; or 2.1.3 Rheumatic heart disease; or 2.1.4 Congenital heart disease; or 2.1.5 Cerebro-vascular disease; or 2.2 Have any of the following chronic respiratory diseases: 2.2.1 Asthma, if on a regular preventative therapy; or		

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2015 (continued)

continued...

- 2.2.2 Other chronic respiratory disease with impaired lung function; or
 - 2.3 Have diabetes; **or**
 - 2.4 Have chronic renal disease; **or**
 - 2.5 Have any cancer, excluding basal and squamous skin cancers if not invasive; **or**
 - 2.6 Have any of the following other conditions:
 - 2.6.1 Autoimmune disease; **or**
 - 2.6.2 Immune suppression **or immune deficiency; or**
 - 2.6.3 HIV; **or**
 - 2.6.4 Transplant recipients; **or**
 - 2.6.5 Neuromuscular and CNS diseases/ **disorders; or**
 - 2.6.6 Haemoglobinopathies; **or**
 - 2.6.7 Are children on long term aspirin; or
 - 2.6.8 Have a cochlear implant, or**
 - 2.6.9 Errors of metabolism at risk of major metabolic decomposition, or**
 - 2.6.10 Pre and post splenectomy, or**
 - 2.6.11 Down syndrome; or**
 - 2.7 Are pregnant, or
 - 2.8 Are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or
 - 3 Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital in the 2015 season.
- Note: The following conditions are excluded from funding:
- asthma not requiring regular preventative therapy; and
 - hypertension and/or dyslipidaemia without evidence of end-organ disease.

211 MEASLES, MUMPS AND RUBELLA VACCINE

- Inj 1000 TCID50 measles, 12500 TCID50 mumps and
1000 TCID50 rubella vial with diluent
– **1% DV Jul-14 to 2017** 0.00 10 **M-M-R-II**

Restricted

A maximum of two doses for any patient meeting the following criteria:

- 1 For primary vaccination in children; or
- 2 For revaccination following immunosuppression; or
- 3 For any individual susceptible to measles, mumps or rubella; **or**
- 4 A maximum of three doses for children who have had their first dose prior to 12 months.**

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

PART III - OPTIONAL PHARMACEUTICALS

214 PREGNANCY TEST - HCG URINE

Cassette – **1% DV Sep-15 to 2017** 17.60 40 test **EasyCheck**

Note – Innovacon hCG One Step Pregnancy Test to be delisted from 1 September 2015.

Effective 1 June 2015

CARDIOVASCULAR SYSTEM

- 42 ISRADIPINE
Cap 2.5 mg

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 June 2015 (continued)

42	NICARDIPINE HYDROCHLORIDE → Inj 2.5 mg per ml, 10 ml vial Restricted Anaesthetist, intensivist or paediatric cardiologist Both: 1. Patient is a paediatric patient; and 2. Any of the following: 2.1 Patient has hypertension requiring urgent treatment with an intravenous agent; or 2.2 Patient has excessive ventricular afterload; or 2.3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.			
45	EZETIMIBE → Tab 10 mg – 1% DV Aug-15 to 2017	3.35	30	Ezemibe
45	EZETIMIBE WITH SIMVASTATIN → Tab 10 mg with simvastatin 10 mg – 1% DV Aug-15 to 2017	5.15	30	Zimybe
	→ Tab 10 mg with simvastatin 20 mg – 1% DV Aug-15 to 2017	6.15	30	Zimybe
	→ Tab 10 mg with simvastatin 40 mg – 1% DV Aug-15 to 2017	7.15	30	Zimybe
	→ Tab 10 mg with simvastatin 80 mg – 1% DV Aug-15 to 2017	8.15	30	Zimybe

DERMATOLOGICALS

52	CLOBETASOL PROPIONATE (↓ price) Crm 0.05%	3.20	30 g	Dermol
	Oint 0.05%	3.20	30 g	Dermol
	Note – Dermol cream 0.05% and oint 0.05% to be delisted from 1 July 2015.			
53	METHOXSALEN [8-METHOXYPORALEN] (presentation change) Tab 10 mg (new listing) Cap 10 mg (delisted 1 June 2015)			

INFECTIONS

69	TOBRAMYCIN → Powder Restricted For addition to orthopaedic bone cement.			
71	CLARITHROMYCIN (amended restriction) → Inj 500 mg vial – 1% DV Mar-15 to 2017	20.40	1	Martindale
	Restricted Infusion Infusion 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or 3 Community-acquired pneumonia (clarithromycin is not to be used as the first-line macrolide).			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 June 2015 (continued)

73 DEMECLOCYCLINE HYDROCHLORIDE
Cap 300 mg

NERVOUS SYSTEM

106	ROPIVACAINE HYDROCHLORIDE (new listing and addition of HSS)			
	Inj 2 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	9.05	5	Ropivacaine Kabi
	Inj 2 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	9.50	5	Ropivacaine Kabi
	Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	10.20	5	Ropivacaine Kabi
	Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	12.50	5	Ropivacaine Kabi
	Inj 10 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	10.90	5	Ropivacaine Kabi
	Inj 10 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	16.30	5	Ropivacaine Kabi
106	ROPIVACAINE HYDROCHLORIDE (↓ price and delisting)			
	Inj 2 mg per ml, 20 ml ampoule	17.50	5	Naropin
	Inj 7.5 mg per ml, 10 ml ampoule	15.00	5	Naropin
	Inj 7.5 mg per ml, 20 ml ampoule	18.90	5	Naropin
	Inj 10 mg per ml, 10 ml ampoule	18.00	5	Naropin
	Note – Naropin inj 2 mg per ml 20 ml, ampoule, inj 7.5 mg per ml, 10 ml and 20 ml ampoule, and inj 10 mg per ml, 10 ml ampoule to be delisted 1 August 2015.			

VACCINES

209	PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE (delisting of vial and removal of HSS)			
	→ Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal serotype)			
	– 1% DV Jul-14 to 2017 31 May 2015	0.00	1	Pneumovax 23
	Note – Pneumovax 23 inj 575 mcg in 0.5 ml vial to be delisted 1 December 2015.			
209	PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE (new listing of prefilled syringe and addition of HSS)			
	→ Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)			
	– 1% DV Jun-15 to 2017	0.00	1	Pneumovax 23
210	INFLUENZA VACCINE (amended restriction)			
	→ Inj 45 mcg in 0.5 ml syringe	90.00	10	Fluarix Influvac
	Restricted			
	Any of the following:			
	1 All people 65 years of age and over; or			
	2 People under 65 years of age who:			
	2.1 Have any of the following cardiovascular diseases:			
	2.1.1 Ischaemic heart disease; or			
	2.1.2 Congestive heart disease; or			
	2.1.3 Rheumatic heart disease; or			
	2.1.4 Congenital heart disease; or			
	2.1.5 Cerebro-vascular disease; or			
	2.2 Have any of the following chronic respiratory diseases:			
	2.2.1 Asthma, if on a regular preventative therapy; or			
	2.2.2 Other chronic respiratory disease with impaired lung function; or			
	2.3 Have diabetes;			

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 June 2015 (continued)

continued...

- 2.4 Have chronic renal disease;
- 2.5 Have any cancer, excluding basal and squamous skin cancers if not invasive;
- 2.6 Have any of the following other conditions:
 - 2.6.1 Autoimmune disease;
 - 2.6.2 Immune suppression;
 - 2.6.3 HIV;
 - 2.6.4 Transplant recipients;
 - 2.6.5 Neuromuscular and CNS diseases;
 - 2.6.6 Haemoglobinopathies;
 - 2.6.7 Are children on long term aspirin; or
- 2.7 Are pregnant, or
- 2.8 Are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or

3 Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital in the 2015 season.

Note: The following conditions are excluded from funding:

- asthma not requiring regular preventative therapy; and
- hypertension and/or dyslipidaemia without evidence of end-organ disease.

Effective 1 May 2015

ALIMENTARY TRACT AND METABOLISM

25 MULTIVITAMIN AND MINERAL SUPPLEMENT

→ Cap

*e.g. Clinicians
Multivitamin and
Mineral Boost*

Restricted

Limited to 3 months treatment

Both:

1. Patient was admitted to hospital with burns; and
2. Any of the following:
 - 2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or
 - 2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or
 - 2.3 Nutritional status prior to admission or dietary intake is poor.

Note: Multivitamin and mineral supplement capsule composition includes vitamin A 250 IU, thiamine 2.5 mg, riboflavin 2.5 mg, nicotinamide 12.5 mg, vitamin B5 10 mg, pyridoxine 5 mg, vitamin B12 6.2 mcg, vitamin C 125 mg, cholecalciferol 2.5 mcg, vitamin E 25 mg, betaine 12.5 mg, biotin 12.5 mcg, boron 250 mcg, calcium 25 mg, choline 6.2 mg, chromium 25 mcg, citric acid 50 mg, citrus bioflavonoid complex 50 mg, co-enzyme Q10 1.2 mg, copper 125 mcg, folic acid 37.5 mcg, inositol 6.2 mg, iodine 25 mcg, iron 250 mcg, L-Glutamine 6.2 mg, magnesium 12.5 mg, molybdenum 12.5 mcg, manganese 0.5 mg, potassium 5 mg, selenium 18.7 mcg, zinc 1.9 mg.

BLOOD AND BLOOD FORMING ORGANS

28 EPOETIN ALFA [ERYTHROPOIETIN ALFA]

→ Inj 8,000 iu in 0.8 ml syringe			
– 5% DV May-15 to 28 Feb 2018	352.69	6	Eprex
→ Inj 40,000 iu in 1 ml syringe			
– 5% DV May-15 to 28 Feb 2018	263.45	1	Eprex

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2015 (continued)

30	OCTOCOG ALFA [RECOMBINANT FACTOR VIII]			
	→ Inj 500 iu vial	500.00	1	Kogenate FS
	→ Inj 1,000 iu vial	1,000.00	1	Kogenate FS
	Note – These are new packs with new Pharmacodes. The old Pharmacodes are to be delisted 1 August 2015.			

34	ALTEPLASE Inj 2 mg vial			
----	----------------------------	--	--	--

CARDIOVASCULAR SYSTEM

45	GLYCERYL TRINITRATE Oral pump spray 400 mcg per dose	4.45	250 dose	Nitrolingual Pump Spray
48	ILOPROST (HSS reinstated) Inj 50 mcg in 0.5 ml ampoule – 1% DV Jul-15 to 2016	89.50	1	Arrow-Iloprost

DERMATOLOGICALS

50	ZINC AND CASTOR OIL Oint, BP – 1% DV Jul-15 to 2017	1.39	20 g	healthE
51	EMULSIFYING OINTMENT (↑ price, addition of HSS, and addition of DV Limit note) Oint BP, 500 g – 1% DV Jul-15 to 2017	2.73	500 g	AFT
	Note: DV limit applies to pack sizes of greater than 200 g.			
52	CLOBETASOL PROPIONATE Crm 0.05% – 1% DV Jul-15 to 2016	3.20	30 g	Clobetasol BNM
	Oint 0.05% – 1% DV Jul-15 to 2016	3.20	30 g	Clobetasol BNM
	Note – Dermol crm 0.05% and oint 0.05% to be delisted from 1 July 2015.			

INFECTIONS

70	CEFUROXIME (HSS suspended) Inj 750 mg vial – 1% DV Nov-14 to 30 Apr 15 2017	3.70	5	Zinacef
	Inj 1.5 g vial – 1% DV Nov-14 to 30 Apr 15 2017	1.30	1	Zinacef
72	AMOXICILLIN (new Pharmacodes) Grans for oral liq 125 mg per 5 ml	0.88	100 ml	Amoxicillin Actavis
	Grans for oral liq 250 mg per 5 ml	0.97	100 ml	Amoxicillin Actavis
	Note – New Pharmacodes listed for this brand. Old Pharmacodes to be delisted from 1 July 2015.			

MUSCULOSKELETAL SYSTEM

92	NEOSTIGMINE METILSULFATE (Pharmacode change) Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	98.00	50	AstraZeneca
	Note – changing from 770612 to 311316.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2015 (continued)

94	ZOLEDRONIC ACID (amended restriction – amended criterion only displayed) → Inj 5 mg per 100 ml, vial 600.00	100 ml	Aclasta
	Restricted Inherited bone fragility disorders Osteogenesis imperfecta Patient has been diagnosed with an inherited bone fragility disorder (e.g. clinical or genetic osteogenesis imperfecta).		
100	IBUPROFEN (↓ price and addition of HSS) Tab long-acting 800 mg – 1% DV Jul-15 to 2018 7.99	30	Brufen SR

NERVOUS SYSTEM

106	ROPIVACAINE HYDROCHLORIDE (↓ price and addition of HSS) Inj 2 mg per ml, 100 ml bag – 1% DV Jul-15 to 2017 60.00	5	Naropin
	Inj 2 mg per ml, 200 ml bag – 1% DV Jul-15 to 2017 79.50	5	Naropin
112	ESCITALOPRAM Tab 10 mg – 1% DV Jul-15 to 2016 1.40	28	Air Flow Products
	Tab 20 mg – 1% DV Jul-15 to 2016 2.40	28	Air Flow Products
	Note – Loxalate tab 10 mg and 20 mg to be delisted from 1 July 2015.		

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

134	ERLOTINIB (amended restriction) → Tab 100 mg – 1% DV Jun-15 to 2018 1,000.00	30	Tarceva
	→ Tab 150 mg – 1% DV Jun-15 to 2018 1,500.00	30	Tarceva
	Restricted Initiation <i>Re-assessment required after 3 months</i> Either: 1 All of the following: 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and 1.3 Any of the following Either: 1.3.1 Patient is treatment naive; or 1.3.2 Both: 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and 1.3.2.2 Patient has not received prior treatment with gefitinib; or and 1.3.3 Both: 1.3.3.1 The patient has discontinued gefitinib within 6 weeks of starting treatment due to intolerance; and 1.3.3.2 The cancer did not progress while on gefitinib; and 1.4 Erlotinib is to be given for a maximum of 3 months, or 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed. Continuation <i>Re-assessment required after 6 months</i> Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.		

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2015 (continued)

134	GEFITINIB (amended restriction) Tab 250 mg	1,700.00	30	Iressa
	Restricted Initiation <i>Re-assessment required after 3 months</i> All of the following Both: 1 Patient has treatment naïve locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and 2 Either: 2.1 Patient is treatment naïve; or 2.2 Both: 2.2.1 The patient has discontinued erlotinib within 6 weeks of starting treatment due to intolerance; and 2.2.2 The cancer did not progress whilst on erlotinib; and 32 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase. Continuation <i>Re-assessment required after 6 months</i> Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.			
138	ABIRATERONE ACETATE → Tab 250 mg	4,276.19	120	Zytiga
	Restricted Initiation Medical oncologist, radiation oncologist or urologist <i>Re-assessment required after 5 months</i> All of the following: 1 Patient has prostate cancer; and 2 Patient has metastases; and 3 Patient's disease is castration resistant; and 4 Either: 4.1 All of the following: 4.1.1 Patient is symptomatic; and 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and 4.1.3 Patient has ECOG performance score of 0-1; and 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or 4.2 All of the following: 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and 4.2.2 Patient has ECOG performance score of 0-2; and 4.2.3 Patient has not had prior treatment with abiraterone. Continuation Medical oncologist, radiation oncologist or urologist <i>Re-assessment required after 5 months</i> All of the following: 1 Significant decrease in serum PSA from baseline; and 2 No evidence of clinical disease progression; and 3 No initiation of taxane chemotherapy with abiraterone; and 4 The treatment remains appropriate and the patient is benefiting from treatment.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2015 (continued)

152	INFLIXIMAB (amended restriction – amended criterion only displayed) → Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020	806.00	1	Remicade
	Restricted			
	Initiation - severe ulcerative colitis			
	Gastroenterologist			
	All of the following:			
	1 Patient has histologically confirmed ulcerative colitis; and			
	2 Either:			
	2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is ≥ 4; or			
	2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is ≥ 65;			
	and			
	3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and			
	4 Surgery (or further surgery) is considered to be clinically inappropriate; and			
	5 Patient must be reassessed for continuation after 3 months of therapy.			
	Continuation - severe ulcerative colitis			
	Gastroenterologist			
	All of the following:			
	1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and			
	2 Either:			
	2.1 Patient is 18 years or older and the SCCAI score has reduced by ≥ 2 points from the SCCAI score when the patient was initiated on infliximab; or			
	2.2 Patient is under 18 years and the PUCAI score has reduced by ≥ 30 points from the PUCAI score when the patient was initiated on infliximab; and			
	3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.			
167	TRASTUZUMAB (amended restriction – amended criterion only displayed) → Inj 150 mg vial	1,350.00	1	Herceptin
	→ Inj 440 mg vial	3,875.00	1	Herceptin
	Restricted			
	Early breast cancer			
	<i>Limited to 12 months' treatment</i>			
	All of the following:			
	1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and			
	2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and			
	3 Any of the following:			
	3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or			
	3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or			
	3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or			
	3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or			
	3.5 3-4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.			

SENSORY ORGANS

177	DICLOFENAC SODIUM Eye drops 0.1%, single dose
-----	--------------------------------------------------

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2015 (continued)

VARIOUS

- 187 MANNITOL
Powder for inhalation *e.g. Aridol*
- 189 ELECTROLYTES
Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride,
1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l
magnesium chloride, 18 mmol/l histidine hydrochloride,
180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l
mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag *e.g. Custodiol-HTK*

SPECIAL FOODS

- 193 CARBOHYDRATE (amended restriction)
Restricted
Use as an additive
Any of the following:
1 Cystic fibrosis; or
2 Chronic kidney disease; or
3 Cancer in children; or
4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
5 Faltering growth in an infant/child; or
6 Bronchopulmonary dysplasia; or
7 Premature and post premature infant; or
8 Inborn errors of metabolism.
Use as a module
For use as a component in a modular formula **made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.**
Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.
- 193 FAT (amended restriction)
Restricted
Use as an additive
Any of the following:
1 Patient has inborn errors of metabolism; or
2 Faltering growth in an infant/child; or
3 Bronchopulmonary dysplasia; or
4 Fat malabsorption; or
5 Lymphangiectasia; or
6 Short bowel syndrome; or
7 Infants with necrotising enterocolitis; or
8 Biliary atresia; or
9 For use in a ketogenic diet; or
10 Chyle leak; or
11 Ascites; or
12 Patient has increased energy requirements, and for whom dietary measures have not been successful.
Use as a module
For use as a component in a modular formula **made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.**
Note: patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

→ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2015 (continued)

194	<p>PROTEIN (amended restriction)</p> <p>Restricted</p> <p>Use as an additive</p> <p>Either:</p> <ol style="list-style-type: none"> 1 Protein losing enteropathy; or 2 High protein needs. <p>Use as a module</p> <p>For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.</p> <p>Note: patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.</p>			
199	<p>FAT-MODIFIED FEED (amended restriction)</p> <p>→ Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat per 100 g, 400 g can</p> <p>Restricted</p> <p>Any of the following:</p> <ol style="list-style-type: none"> 1 Patient has metabolic disorders of fat metabolism; or 2 Patient has a chyle leak; or 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults. <p>Note: patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.</p>			<i>e.g. Monogen</i>
201	<p>AMINO ACID FORMULA (amended restriction)</p> <p>→ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can</p> <p>→ Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can</p> <p>→ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can 53.00</p> <p>→ Powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can</p> <p>→ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can 53.00</p> <p>→ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can 53.00</p> <p>→ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can 53.00</p> <p>→ Powder 6 g protein, 31.5 g carbohydrate and 5.88 g fat per sachet 6.00</p> <p>Restricted</p> <p>Initiation</p> <p>Any of the following:</p> <ol style="list-style-type: none"> 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or 2 History of anaphylaxis to cows' milk protein formula or dairy products; or 			<p><i>e.g. Neocate</i></p> <p><i>e.g. Neocate LCP</i></p> <p>Neocate Gold (Unflavoured)</p> <p><i>e.g. Neocate Advance</i></p> <p>Neocate Advance (Vanilla)</p> <p>Elecare LCP (Unflavoured)</p> <p>Elecare (Unflavoured) Elecare (Vanilla)</p> <p>Vivonex Paediatric</p>

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2015 (continued)

continued...

3 Eosinophilic oesophagitis.

Note: a reasonable trial is defined as a 2-4 week trial.

Continuation

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

201 EXTENSIVELY HYDROLYSED FORMULA (amended restriction – amended criterion only displayed)

➔ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can

*e.g. Gold Pepti Junior
Karicare Aptamil*

Restricted

Initiation - new patients

Any of the following:

1 Both:

1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and

1.2 Either:

1.2.1 Soy milk formula has been **reasonably** trialled without resolution of symptoms; or

1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or

2 Severe malabsorption; or

3 Short bowel syndrome; or

4 Intractable diarrhoea; or

5 Biliary atresia; or

6 Cholestatic liver diseases causing malabsorption; or

7 Cystic fibrosis; or

8 Proven fat malabsorption; or

9 Severe intestinal motility disorders causing significant malabsorption; or

10 Intestinal failure.

Note: A reasonable trial is defined as a 2-4 week trial.

203 PAEDIATRIC PRODUCTS (amended restriction)

Restricted

Both:

1 Child is aged one to ten years; and

2 Any of the following:

2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or

2.2 Any condition causing malabsorption; or

2.3 Faltering growth in an infant/child; or

2.4 Increased nutritional requirements; or

2.5 The child is being transitioned from TPN or tube feeding to oral feeding; or

2.6 The child has eaten, or is expected to eat, little or nothing for 3 days.

Changes to Section H Part II – effective 1 April 2015

ALIMENTARY TRACT AND METABOLISM

15	MESALAZINE (addition of HSS) Suppos 1 g – 1% DV Jun-15 to 2018	54.60	30	Pentasa
23	FERROUS FUMARATE (↓ price and addition of HSS) Tab 200 mg (65 mg elemental) – 1% DV Jun-15 to 2018	2.89	100	Ferro-tab

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2015 (continued)

BLOOD AND BLOOD FORMING ORGANS

34	CALCIUM GLUCONATE († price) Inj 10%, 10 ml ampoule	34.24	10	Hospira
36	SODIUM CHLORIDE → Inj 0.9%, 3 ml syringe – 1% DV Jun-15 to 2018	10.65	30	BD PosiFlush
	Restricted For use in flushing of in-situ vascular access devices only.			
	→ Inj 0.9%, 5 ml syringe – 1% DV Jun-15 to 2018	10.80	30	BD PosiFlush
	Restricted For use in flushing of in-situ vascular access devices only.			
	→ Inj 0.9%, 10 ml syringe – 1% DV Jun-15 to 2018	11.25	30	BD PosiFlush
	Restricted For use in flushing of in-situ vascular access devices only.			

CARDIOVASCULAR SYSTEM

41	CARVEDILOL (new listing and addition of HSS) Tab 6.25 mg – 1% DV Jun-15 to 2017	3.90	60	Dicarz
	Tab 12.5 mg – 1% DV Jun-15 to 2017	5.10	60	Dicarz
	Tab 25 mg – 1% DV Jun-15 to 2017	6.30	60	Dicarz
	Note – Dilatrend tab 6.25 mg, 12.5 mg and 25 mg to be delisted from 1 June 2015.			
47	PAPAVERINE HYDROCHLORIDE († price) Inj 12 mg per ml, 10 ml ampoule	217.90	5	Hospira

DERMATOLOGICALS

51	AQUEOUS CREAM Crm 100 g	1.23	100 g	AFT
	Note: DV limit applies to the pack sizes of 100 g or less.			
	Crm 500 g	1.96	500 g	AFT
	Note: DV limit applies to the pack sizes of greater than 100 g.			
51	EMULSIFYING OINTMENT Oint BP – 1% DV Apr-15 to 2017	1.84	100 g	Jaychem
	Note: DV limit applies to pack sizes of less greater than 200 g.			
	Oint BP, 500 g	3.04	500 g	AFT
	Note: DV limit applies to pack sizes of greater than 100 g.			
52	BETAMETHASONE VALERATE Crm 0.1% – 1% DV Jun-15 to 2018	3.15	50 g	Beta Cream
	Oint 0.1% – 1% DV Jun-15 to 2018	3.15	50 g	Beta Ointment
52	HYDROCORTISONE Crm 1%, 500 g	14.00	500 g	Pharmacy Health
	Note: DV limit applies to the pack sizes of greater than 100 g.			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2015 (continued)

HORMONE PREPARATIONS

61	OESTRADIOL VALERATE			
	Tab 1 mg – 1% DV Jun-15 to 2018	12.36	84	Progynova
	Tab 2 mg – 1% DV Jun-15 to 2018	12.36	84	Progynova
62	NORETHISTERONE (↓ price and addition of HSS)			
	Tab 5 mg – 1% DV Jun-15 to 2018	18.29	100	Primolut N
68	TERLIPRESSIN (↓ price and addition of HSS)			
	Inj 1 mg per 8.5 ml ampoule – 1% DV Jun-15 to 2018	215.00	5	Glypressin

INFECTIONS

69	IMIPENEM WITH CILASTATIN			
	→ Inj 500 mg with 500 mg cilastatin vial			
	– 1% DV Jun-15 to 2017	13.79	1	Imipenem + Cilastatin RBX
	Note – Primaxin inj 500 mg with 500 mg cilastin to be delisted from 1 June 2015.			
72	PHENOXYMETHYLPENICILLIN [PENICILLIN V] (↓ price and addition of HSS)			
	Cap 250 mg – 1% DV Jun-15 to 2018	2.88	50	Cilicaine VK
	Cap 500 mg – 1% DV Jun-15 to 2018	4.73	50	Cilicaine VK
76	FLUCONAZOLE (↑ price)			
	→ Oral liquid 50 mg per 5 ml	98.50	35 ml	Diflucan
89	VALGANCICLOVIR (↓ price and addition of HSS)			
	→ Tab 450 mg – 1% DV Jun-15 to 2018	1,050.00	60	Valcyte

MUSCULOSKELETAL SYSTEM

100	IBUPROFEN			
	Inj 10 mg per ml, 2 ml vial			
101	NAPROXEN			
	Tab long-acting 750 mg – 1% DV Jun-15 to 2018	18.00	90	Naprosyn SR 750
	Tab long-acting 1 g – 1% DV Jun-15 to 2018	21.00	90	Naprosyn SR 1000

NERVOUS SYSTEM

102	APOMORPHINE HYDROCHLORIDE (↑ price)			
	Inj 10 mg per ml, 2 ml ampoule	119.00	5	Apomine
104	BUPIVACAINE HYDROCHLORIDE			
	Inj 5 mg per ml, 10 ml ampoule	35.00	50	Marcain
	Note – Marcain inj 5 mg per ml, 10 ml ampoule to be delisted 1 June 2015.			
122	LORAZEPAM (addition of HSS)			
	Tab 1 mg – 1% DV Jun-15 to 2018 (↑ price)	10.79	250	Ativan
	Tab 2.5 mg – 1% DV Jun-15 to 2018 (↑ price)	13.88	100	Ativan

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2015 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

134	ERLOTINIB (↓ price and addition of HSS)			
	→ Tab 100 mg – 1% DV Jun-15 to 2018	1,000.00	30	Tarceva
	→ Tab 150 mg – 1% DV Jun-15 to 2018	1,500.00	30	Tarceva
138	VINBLASTINE SULPHATE (↑ price)			
	Inj 1 mg per ml, 10 ml vial	186.46	5	Hospira
140	TAMOXIFEN CITRATE			
	Tab 10 mg	2.63	60	Genox
	Note – Genox tab 10 mg, 60 tablet pack size, to be delisted from 1 June 2015. The 100 tablet pack size remains available.			

Index

Pharmaceuticals and brands

A	
Abiraterone acetate	28
Acetadote	18
Acetylcysteine.....	18
Aclasta	27
Act-HIB.....	19
Allersoothe.....	17
Alteplase.....	26
AmBisome	14
Amino acid formula	31
Amoxicillin	26
Amoxicillin Actavis	26
Amoxicillin with clavulanic acid	13
Amphotericin B	14
Andriol Testocaps	13
Anexate.....	18
Apo-Azithromycin	13
Apo-Ciclopirox	12
Apo-Clomipramine	15
Apomine	34
Apomorphine hydrochloride	34
Aqueous cream.....	33
Arrow-Doxorubicin	16
Arrow-Etidronate	14
Arrow-Iloprost.....	12, 26
Arrow-Quinapril 5.....	11
Arrow-Quinapril 10.....	11
Arrow-Quinapril 20.....	11
Asthalin	17
Atenolol	11
Ativan	34
Azithromycin.....	13
B	
Baclofen	14
BD PosiFlush	10, 33
Benzathine benzylpenicillin	13
Beta Cream	33
Betamethasone dipropionate with calcipotriol.....	12
Betamethasone valerate	33
Beta Ointment	33
Bicillin LA.....	13
BiCNU.....	16
Biodone	15
Biodone Extra Forte	15
Biodone Forte.....	15
Boostrix.....	19
Brufen SR	27
Bupivacaine hydrochloride.....	15, 34
C	
Cabergoline.....	13
Calcium gluconate	33
Candesartan cilexetil	11
Candestar	11
Carbohydrate	30
Carboplatin	17
Cardinol LA	11
Carmustine	16
Carvedilol.....	33
Cefalexin.....	13
Cefalexin Sandoz.....	13
Cefuroxime	26
Celiprolol	11
Celol	11
Chlorafast.....	17
Chloramphenicol	17
Chlorhexidine gluconate	10, 12
Ciclopirox olamine.....	12
Ciclosporin	17
Cilicaine VK.....	34
Clarithromycin.....	23
Clobetasol BNM	26
Clobetasol propionate.....	23, 26
Clomipramine hydrochloride.....	15
Clonazepam.....	16
Clonidine BNM	11
Clonidine hydrochloride.....	11
Crotamiton	12
Cubicin	14
Cyklokapron.....	10
D	
Daivobet	12
Daptomycin	14
DBL Acetylcysteine	18
DBL Carboplatin.....	17
DBL Flucloxacillin	14
DBL Sterile Dopamine Concentrate	11
Decozol	10
Demeclocycline hydrochloride.....	24
Dermol.....	23
Dicarz	33
Diclofenac sodium	29
Diflucan	34
Diphtheria, tetanus and pertussis vaccine	19
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	18
Diurin 40.....	11
Dopamine hydrochloride	11
Dostinex	13
Doxorubicin hydrochloride.....	16
Duolin.....	17
Duovisc	18

Index

Pharmaceuticals and brands

E		
EasyCheck.....	22	
Efavirenz.....	14	
Efexor XR.....	15	
Efudix.....	12	
Elecare LCP (Unflavoured).....	31	
Elecare (Unflavoured).....	31	
Elecare (Vanilla).....	31	
Electrolytes.....	30	
Elocon.....	12	
Emulsifying ointment.....	26, 33	
Enalapril maleate.....	11	
Entacapone.....	15	
Entapone.....	15	
Epiilm IV.....	15	
Epoetin alfa.....	25	
Eprex.....	25	
Erlotinib.....	27, 35	
Ertapenem.....	13	
Erythropoietin alfa.....	25	
Escitalopram.....	27	
Ethics Enalapril.....	11	
Ethinylloestradiol.....	13	
Etidronate disodium.....	14	
Extensively hydrolysed formula.....	32	
Ezemibe.....	23	
Ezetimibe.....	23	
Ezetimibe with simvastatin.....	23	
F		
Fat.....	30	
Fat-modified feed.....	31	
Felodipine.....	11	
Fentanyl.....	15	
Ferro-tab.....	32	
Ferrous fumarate.....	32	
Flixonase Hayfever & Allergy.....	17	
Fluarix.....	21, 24	
Flucloxacillin.....	13, 14	
Flucloxin.....	14	
Fluconazole.....	34	
Fludarabine phosphate.....	16	
Fludara Oral.....	16	
Flumazenil.....	18	
Fluorometholone.....	17	
Fluorouracil sodium.....	12	
Fluticasone propionate.....	17	
FML.....	17	
Furosemide (frusemide).....	11	
G		
Gardasil.....	21	
Gastrosoothe.....	10	
Gefitinib.....	28	
Genox.....	35	
Gentamicin sulphate.....	13	
Glipizide.....	10	
Glycerol.....	10	
Glyceryl trinitrate.....	26	
Glypressin.....	34	
H		
Habitrol.....	16	
Habitrol (Classic).....	16	
Habitrol (Fruit).....	16	
Habitrol (Mint).....	16	
Haemophilus influenzae type B vaccine.....	19	
HBvaxPRO.....	21	
Healon GV.....	18	
Hepatitis B recombinant vaccine.....	21	
Herceptin.....	29	
Human papillomavirus (6, 11, 16 and 18) vaccine [HPV].....	21	
Hyaluronic acid.....	10, 18	
Hydrocortisone.....	13, 33	
Hydrocortisone with miconazole.....	12	
Hydroxocobalamin.....	10	
Hydroxychloroquine.....	14	
Hylo-Fresh.....	18	
Hyoscine butylbromide.....	10	
Hysite.....	18	
I		
Ibuprofen.....	27, 34	
Iloprost.....	12, 26	
Imipenem + Cilastin RBX.....	34	
Imipenem with cilastatin.....	34	
Infanrix-hexa.....	18	
Infliximab.....	29	
Influenza vaccine.....	21, 24	
Influvac.....	21, 24	
Invanz.....	13	
Iressa.....	28	
Irinotecan Actavis 40.....	16	
Irinotecan Actavis 100.....	16	
Irinotecan hydrochloride.....	16	
Isoniazid.....	14	
Isoniazid with rifampicin.....	14	
Isradipine.....	22	
Itch-Soothe.....	12	
K		
Kogenate FS.....	26	
L		
Latanoprost.....	18	
Lidocaine hydrochloride.....	15	
Lignocaine.....	15	

Index

Pharmaceuticals and brands

Linezolid	14	Papaverine hydrochloride	33
Lioresal Intrathecal	14	Paraffin	12
Lithicarb FC	15	Paxam	16
Lithium carbonate	15	Penicillin V	34
Lorazepam	34	Pentasa	10, 32
M		Phenoxyethylpenicillin	34
m-Amoxiclav	13	Pizotifen	15
Mannitol	30	Plaquenil	14
Marcaïn	15, 34	Plendil ER	11
Measles, mumps and rubella vaccine	22	Pneumococcal (PCV13) conjugate vaccine	20
Menactra	19	Pneumococcal (PPV23) polysaccharide vaccine	24
Meningococcal (a, c, y and w-135) conjugate vaccine	19	Pneumovax 23	24
Meningococcal c conjugate vaccine	20	Potassium chloride	10
Mesalazine	10, 32	Pregnancy test - HCG urine	22
Methadone hydrochloride	15	Prevenar 13	20
Methatabs	15	Primolut N	34
Methotrexate	16	Progynova	34
Methoxsalen [8-methoxypsoralen]	23	Promethazine hydrochloride	17
Miconazole	10	Propranolol	11
Micreme H	12	Protein	31
Minidiab	10	Provisc	18
Mitozantrone	16	Q	
Mitozantrone Ebewe	16	Quinapril	11
M-M-R-II	22	R	
Mometasone furoate	12	Recombinant factor VIII	26
Multivitamin and mineral supplement	25	Remicade	29
Mylan Atenolol	11	Resonium A	11
N		Rifinah	14
Naprosyn SR 750	34	Ropivacaine hydrochloride	24, 27
Naprosyn SR 1000	34	Ropivacaine Kabi	24
Naproxen	14, 34	S	
Naropin	24, 27	Salbutamol	17
Navelbine	17	Salbutamol with ipratropium bromide	17
Neisvac-C	20	Sandimmun	17
Neo-B12	10	Sandomigran	15
Neocate Advance (Vanilla)	31	Sildenafil	12
Neocate Gold (Unflavoured)	31	Sodium chloride	10, 33
Neostigmine metilsulfate	26	Sodium hyaluronate	10, 18
Nicardipine hydrochloride	23	Sodium hyaluronate with chondroitin sulphate	18
Nicotine	16	Sodium polystyrene sulphonate	11
Nitrolingual Pump Spray	26	Sodium valproate	15
Noflam 250	14	Span-K	10
Noflam 500	14	Staphlex	13
Norethisterone	34	Stocrin	14
O		Syntometrine	12
Octocog alfa	26	T	
Oestradiol valerate	34	Tamoxifen citrate	35
Oxytocin with ergometrine maleate	12	Tarceva	27, 35
P		Terlipressin	34
Paediatric products	32	Testosterone undecanoate	13
		TMP	14

Index

Pharmaceuticals and brands

Tobramycin.....	23	Vedafil	12
Tranexamic acid.....	10	Venlafaxine	15
Trastuzumab	29	Vinblastine sulphate	35
Trexate.....	16	Vinorelbine.....	17
Trimethoprim	14	Vivonex Paediatric.....	31
Tropisetron	15	Z	
Tropisetron-AFT	15	Zimybe.....	23
U		Zinacef.....	26
Urex Forte	11	Zinc and castor oil.....	26
V		Zoledronic acid	27
Valcyte.....	34	Zytiga.....	28
Valganciclovir	34	Zyvox.....	14

New Zealand
Permit No. 478



Hospital Medicines List queries:

Freephone Information line 0800 66 00 50

Email: HML@pharmac.govt.nz

www.pharmac.health.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz
Freephone Information line (9am-5pm weekdays) 0800 66 00 50

ISSN 1172-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

newzealand.govt.nz

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand